source
- STAT+: FDA to reconsider treatment for rare cancer after its surprise rejectionThe companies developing Ebvallo reached an agreement with the FDA to address its main reason for rejecting the drug.STAT · 2mo ago↗ source
- Hospital shootings steadily increased since 2000What the FDA has lost, why hantavirus isn't the next pandemic, and more health news from Morning RoundsSTAT · 2mo ago↗ source
- STAT+: Next-gen Duchenne drug from Entrada disappointsA next-gen Duchenne therapy from Entrada Therapeutics fell short in an early study, as a number of companies race to make improved drugs.STAT · 2mo ago↗ source